title: [Ecological immunodeficiency: immunogenetic aspects of its etiology and correction].
abstract: The examinations of auto-transport Kazakh drivers have indicated that there is a significant reduction in some immunological parameters HLA-B5 and HLA-DR5-proliferative responses of lymphocytes to mitogens, production of interleukin-1 and interleukin-2, activity of NK and LAK-cells. It is suggested that these impairments occur with their long-term exposure to automobile transport effluents (ATE), since the same changes in immunological parameters were found previously in the experiments with animals exposed to ATE for a long time. Some of the detected immunoresponsive disorders are associated with the availability of definite HLA antigens, such as HLA-B5 and HLA-P5. The new immunomodulating agents thymohexin (TH) and phyto-extraction drugs C4 and C6 used in vitro substantially restored the lower functional activity of immunocompetent cells and production of cytokines (thymohexin was particularly effective). The most marked recovery was observed in the drivers with the phenotype HLA-B6+ and HLA-P5+, i.e. in persons with maximally ATE-reduced immunological parameters.
authors.forename: L A
authors.initials: LA
authors.lastname: Pevnitskiĭ
authors.forename: G K
authors.initials: GK
authors.lastname: Baĭmukanova
authors.forename: V M
authors.initials: VM
authors.lastname: Pisarev
authors.forename: V V
authors.initials: VV
authors.lastname: Lebedev
authors.forename: A D
authors.initials: AD
authors.lastname: Bakuridze
authors.forename: M Sh
authors.initials: MSh
authors.lastname: Kurtsikidze
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D001334:Automobile Driving; D015235:HLA-B Antigens / Q000032:analysis; D015805:HLA-DR5 Antigen / Q000032:analysis; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D009784:Occupational Diseases / Q000139:chemically induced; D009842:Oligopeptides / Q000627:therapeutic use; D001335:Vehicle Emissions / Q000009:adverse effects
chemical_list: D000276:Adjuvants, Immunologic; D015235:HLA-B Antigens; C035270:HLA-B5 antigen; D015805:HLA-DR5 Antigen; D009842:Oligopeptides; D001335:Vehicle Emissions; C080035:thymohexin